RxDoctor Payments DataLook up a doctor →

Ronald Wauters, MD

Psychiatry · Searcy, ARNPI 1801854195

Payments from drug & device makers

$204,235in general payments, 2019–2025

Across 1,098 payments — averaging $186.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$161K
  • Idorsia Pharmaceuticals US Inc$28K
  • AbbVie$3K
  • Johnson & Johnson$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • plus $7K from 26 others

What the payments were for

  • Consulting fees$5,7503%
  • Speaking & faculty fees$160,47579%
  • Travel & lodging$17,0728%
  • Food & beverage$20,48810%
  • Education$4500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$204,235 in reported general payments places this provider in the 95th percentile of 235 psychiatry providers in Arkansas.

See all psychiatry providers in Arkansas

Medicare billing

Part B allowed, 2024
$15,389
Medicare patients
58
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$102,834
VraylarCariprazine Hcl18$31,655
Zyprexa ZydisOlanzapine12$31,423
Aripiprazole97$16,570
RexultiBrexpiprazole11$16,483
Quetiapine Fumarate151$3,340
Bupropion XlBupropion Hcl154$2,558
Clozapine51$2,285
Gabapentin157$2,216
Duloxetine Hcl122$1,800
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine52$1,750
Divalproex Sodium ErDivalproex Sodium42$1,709
Alprazolam181$1,194
Oxcarbazepine26$1,028
Clonazepam76$933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,123$102,83412 claims
AbbVieVraylar$2,923$31,65518 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,833$16,48311 claims
Almatica Pharma LLCSertraline Hcl$38$44066 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 psychiatry providers in Arkansas.

Other psychiatry in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →